Theradaptive utilizes its proprietary THX1 platform to engineer recombinant proteins that enhance targeted delivery for various clinical applications, including spinal fusion and soft tissue repair. This approach improves therapeutic efficacy while minimizing off-target side effects, addressing the limitations of traditional protein-based treatments.
Funding
$32.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MSFounders
Product
Problem
Traditional protein-based therapeutics often lack precise targeting, leading to reduced efficacy and increased off-target side effects. This is particularly problematic when treating conditions requiring localized tissue regeneration or repair, such as spinal fusion and soft tissue injuries. Existing methods struggle to deliver therapeutic proteins directly to the affected area, limiting their effectiveness.
Solution
Theradaptive engineers recombinant proteins using its THX1 platform to enhance targeted delivery for various clinical applications. By modifying proteins to bind specifically to target tissues, Theradaptive improves therapeutic efficacy while minimizing off-target side effects. This approach enables safer and more effective delivery of therapeutics directly to the site of injury or disease, addressing the limitations of traditional protein-based treatments. The platform has applications in spinal fusion, orthopedics, soft tissue repair, and targeted chemotherapeutics.
Target Audience
The primary target audience includes medical professionals and researchers in orthopedics, spinal surgery, and regenerative medicine seeking improved protein-based therapeutics with enhanced targeting capabilities.
Features
- THX1 platform for engineering material-binding variants of recombinant proteins
- Modified proteins designed for targeted delivery to specific tissues
- Enhanced therapeutic efficacy through precise localization of treatment
- Reduced off-target side effects due to improved targeting
- Broad applicability across various clinical indications, including spinal fusion, orthopedics, and soft tissue repair